Zepbound Obesity Treatment

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Zepbound trims more belly fat than Wegovy, study shows

The impact on waistlines is crucial because they are a surrogate measure for the dangerous fat that gets stored around organs in the abdomen.

· 2d

Zepbound outperforms Wegovy in head-to-head weight loss study

· 2d · on MSN

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

· 1d

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 2d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

MedPage Today on MSN1d

Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

InvestorsHub on MSN7h

Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna (NASDAQ: SEPN) to co-develop oral small molecule therapies targeting obesity, type 2 diabetes,

Pharmaceutical Technology2h

Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

pharmaphorum2d

More data back Zepbound over Wegovy for weight loss

"These data confirm Zepbound as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan," said Leonard Glass ...

STAT2d

Pharmalittle: We’re reading about Trump drug-pricing plan, obesity drug trial data, and more

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less than Americans do